ClinicalTrials.gg
WithdrawnNCT04422795Updated Apr 7, 2023

The Evaluation of External Thermomechanical Stimulation for Pain Reduction in Patients Undergoing Nail Injection

A Phase 4 interventional study of External thermomechanical device delivering cold and vibration stimuli and External thermomechanical device without delivering cold and vibration stimuli in Nail Diseases, sponsored by Weill Medical College of Cornell University. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-07.

Sponsored by Weill Medical College of Cornell University · Phase 4, Interventional, and Supportive care

Why this study was withdrawn
Due to reallocation of resources, this study could not be initiated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of a thermomechanical device delivering vibration and cold stimuli in lowering pain during intramatricial nail injections

02

Conditions studied

  • Nail Diseases

Keywords

  • Nails
  • Thermomechanical stimulation
  • Intralesional injection
03

In context

Lead sponsor

Weill Medical College of Cornell University is the lead sponsor of 892 studies on the registry; 165 are open to participants now.

Of its 123 completed or terminated interventional studies of FDA-regulated products, 94 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 years or older
  • Must understand and voluntarily sign an form
  • All patients undergoing intramatricial nail injections at the Weill Cornell Medicine (WCM) Department of Dermatology
  • Willingness to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Inability of the patient to provide written for any reason
  • Failure to have nail injection performed
  • Likely inability to comply with the study protocol or cooperate fully with the research team
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    External thermomechanical device delivering stimuli

    The thermomechanical device is placed on the digit proximally to the injection site with the ice wings frozen and the vibration mechanism switched on.

    Device: External thermomechanical device delivering cold and vibration stimuli

  • Placebo comparator
    External thermomechanical device without delivering stimuli

    The thermomechanical device is placed on the digit proximally to the injection site with the ice wings at room temperature (unfrozen) and the vibration mechanism switched off.

    Device: External thermomechanical device without delivering cold and vibration stimuli

  • Active comparator
    Nail injection with ethyl chloride skin refrigerant spray

    Ethyl chloride skin refrigerant spray is applied to the area of injection immediately before needle insertion

    Drug: Ethyl chloride skin refrigerant spray

Interventions

  • DeviceExternal thermomechanical device delivering cold and vibration stimuli

    the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings frozen and the vibration mechanism switched on, delivering vibration and cold stimuli to the area for 30 seconds before the intramatricial injection and until needle withdrawal

  • DeviceExternal thermomechanical device without delivering cold and vibration stimuli

    the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings at unfrozen and the vibration mechanism switched off, for 30 seconds before the intramatricial injection and until needle withdrawal

  • DrugEthyl chloride skin refrigerant spray

    Ethyl chloride skin refrigerant spray is applied to the area of injection for 3 seconds immediately before needle insertion

06

What researchers measure

Primary outcomes

  1. The level of pain and change in pain between each time point will be assessed using the Wong-Baker FACES scale with use of thermomechanical device delivering stimuli, without delivering stimuli, and with use of ethyl chloride skin refrigerant spray.

    Pain will be self-reported, using the Wong-Baker FACES (0-10, with 0 representing absence of pain and 10 unbearable pain). Participants will be questioned about their level of pain in their nail prior to treatment, immediately after the needle insertion, during infiltration, and 5 seconds after needle extraction

    Time frame: prior to treatment, immediately after the needle insertion, during infiltration and 5 seconds after needle extraction

Secondary outcomes

  1. Number of participants with at least one adverse event

    Adverse events will only include those that are determined to be related to the study device

    Time frame: Patients will be followed for 3 days following their nail injection

07

Study locations

1 site
  • Weill Cornell Medicine
    New York, New York 10021, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2024; primary completion for Feb 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2020
First posted
Jun 9, 2020
StartEst.
Feb 2024
Primary completionEst.
Feb 2025
CompletionEst.
Jul 2025
Last update
Apr 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04422795
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Feb 2024 (estimated)
Primary completion
Feb 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Apr 7, 2023

Study contacts

Shari R Lipner, MD, PhD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion